Fundz
New|Fundz now works inside Claude2 min

Timing. Relevance. Relationships.

Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.

Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015
Back to SEC Filings
Other EventsItem 8.01 · 8-KMEDIUM RiskNeutral

Tenax Therapeutics, Inc.

The company reported another event it considers important. An 8-K is the notice a US public company must file within four business days of a major event.

tenaxthera.com
Filed: Oct 8, 2026Chapell Hill, North CarolinaCIK: 0000034956Healthcare
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Tenax Therapeutics announced an enrichment strategy for its LEVEL-2 clinical trial of TNX-103 based on Phase 3 LEVEL trial insights, temporarily pausing recruitment to implement new enrollment criteria focused on pulmonary hypertension and heart failure patients, while requesting a Type C meeting with the FDA to discuss levosimendan development.

Key Takeaways

LEVEL-2 trial recruitment has been temporarily paused to implement amended enrollment criteria targeting specific patient populations (PH-HFpEF)

The enrichment strategy is based on learnings from the completed Phase 3 LEVEL trial, indicating data-driven optimization of clinical development

1 more takeaway

Related Filings (1)

1 more filing from Tenax Therapeutics, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateOct 8, 2026
Item8.01
CategoryOther Events
CIK0000034956
Accession #0001193125-26-417939
Risk LevelMEDIUM
SentimentNeutral
Signalinformational
Topics
regulatoryproduct launch

What This Means

Other material events not covered by specific item numbers. The content of the filing determines significance.
View Full Filing on SEC.govBrowse More Filings

Tenax Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.